Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-
derived GBM tumor cells

Supplementary Materials
Supplementary Figure 1: Uncoated-Let-NP control experiment. SEM imaging displays the fact that there are no maintained observable morphological changes 36 hours post-NP treatment with uncoated-Letrozole loaded-NPs. NPs are evident on the GBM cell surface (denoted by red arrows) and cell morphology is altered after initial NP addition, however the significant and sustained cell modification which is noted in Figure 4C is not recapitulated in the control NP experiment; suggesting that the effect is due to the introduction of Letrozole within the cell itself.
Summary of clinical characteristics of patient-derived glioblastoma xenografts (G46, G59, G64, G76, G79, G80, G84, G85 and G91) by the Mayo Clinic Brain Tumor SPORE, in addition to primary (MZ-327 and RN1) and recurrent (MZ-256 and MZ-304) GBM patient-derived cell lines. Summary table of characterization of synthesized nanoparticles, uncoated (PLGA-NP) and anti-GD2-ch14.18/CHO coated (anti-GD2-ch14.18/CHO-PLGA-NPs) nanoparticles. Average sizing, encapsulation efficiency and charge is included.
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